Search: WFRF:(O'Dorisio Thomas M.) >
Pasireotide (SOM230...
Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR : results from a phase II study
-
Kvols, Larry K (author)
-
- Öberg, Kjell E (author)
- Uppsala universitet,Onkologisk endokrinologi
-
O'Dorisio, Thomas M (author)
-
show more...
-
Mohideen, Pharis (author)
-
de Herder, Wouter W (author)
-
Arnold, Rudolf (author)
-
Hu, Ke (author)
-
Zhang, Yilong (author)
-
Hughes, Gareth (author)
-
Anthony, Lowell (author)
-
Wiedenmann, Bertram (author)
-
show less...
-
(creator_code:org_t)
- 2012
- 2012
- English.
-
In: Endocrine-related cancer. - 1479-6821. ; 19:5, s. 657-66
- Related links:
-
https://urn.kb.se/re...
-
show more...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- Pasireotide (SOM230) is a novel multireceptor-targeted somatostatin (sst) analog with high binding affinity for sst receptor subtype 1, 2, 3 (sst(1,2,3)) and sst(5). Because of this binding profile, pasireotide may offer symptom control in patients with neuroendocrine tumors (NETs) and carcinoid syndrome no longer responsive to octreotide LAR. This was a phase II, open-label, multicenter study of pasireotide in patients with advanced NET whose symptoms of carcinoid syndrome (diarrhea/flushing) were inadequately controlled by octreotide LAR. Patients received s.c. pasireotide 150 μg twice daily (bid), escalated to a maximum dose of 1200 μg bid until a clinical response was achieved. Forty-four patients were evaluated for efficacy and 45 for tolerability. Pasireotide 600-900 μg s.c. bid effectively controlled the symptoms of diarrhea and flushing in 27% of patients. Evaluation of tumor response in 23 patients showed 13 with stable disease and ten with progressive disease at study end. The most common drug-related adverse events were nausea (27%), abdominal pain (20%), weight loss (20%), and hyperglycemia (16%) and most were of mild or moderate severity. Pasireotide 600-900 μg s.c. bid was effective and generally well tolerated in controlling the symptoms of carcinoid syndrome in 27% of patients with advanced NET refractory or resistant to octreotide LAR therapy.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database
- By the author/editor
-
Kvols, Larry K
-
Öberg, Kjell E
-
O'Dorisio, Thoma ...
-
Mohideen, Pharis
-
de Herder, Woute ...
-
Arnold, Rudolf
-
show more...
-
Hu, Ke
-
Zhang, Yilong
-
Hughes, Gareth
-
Anthony, Lowell
-
Wiedenmann, Bert ...
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Cancer and Oncol ...
- Articles in the publication
-
Endocrine-relate ...
- By the university
-
Uppsala University